Opinion

Video

Key Considerations for Selecting IPF Treatment

Author(s):

Justin Oldham, MD, MS

Decision-making factors surrounding optimal IPF treatment selection are evaluated by Justin Oldham, MD, MS.

Video content above is prompted by the following:

  1. Based on your clinical experience, what patient characteristics are considered when selecting a treatment regimen?
  2. What challenges are often present with current antifibrotic agents (i.e., tolerability, adverse effects)?
Related Videos
A panel of 4 experts on chronic spontaneous urticaria
A panel of 4 experts on chronic spontaneous urticaria
1 KOL is featured in this series.
Related Content
leukemia word map | Image Credit: dizain-stock.adobe.com
June 28th 2024

Infection Risk With BTK Inhibitors Low, New CLL Study Finds

Jared Kaltwasser
Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.
Managed Care Cast
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Ravin Ratan, MD, MEd
June 28th 2024

Zeroing in on Sarcoma Subtypes to Optimize Treatment Outcomes

Maggie L. Shaw
The field of sarcoma study is getting more specific, with clinical investigations drilling down to more specific subtypes of soft tissue sarcoma for better targeted therapies.
Managed Care Cast
May 9th 2024

Frameworks for Advancing Health Equity: Urban Health Outreach

Giuliana Grossi
In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Person taking pills | Image credit: fizkes – stock.adobe.com
June 28th 2024

Many Patients With IPF Continue on Antifibrotics for 3 Years

Hayden E. Klein
However, registry data also showed no significant difference in transplant-free survival and time to pulmonary function decline between patients receiving antifibrotics vs placebo.
skin cancer | Image Credit: uffoow-stock.adobe.com
June 28th 2024

Certain Melanoma Subtype May Be More Sensitive to NK, T Cells

AJMC Contributor
Of 7 subtypes identified 10,000 melanoma cells, C4 Melanoma COCO1A was the only to show indications of being more sensitive to natural killer (NK) and T cells.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo